Evidence map›Paper›PMID 36932402›Full record

ArticleCancer cell international2023

Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis.

Maren Nicole Stillger, Chia-Yi Chen, Zon Weng Lai, Mujia Li, Agnes Schäfer, Axel Pagenstecher, Christopher Nimsky, Jörg Walter Bartsch, Oliver Schilling

Open access · goldFull text read
In one paragraph

Article in Cancer cell international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Cell death in glioblastoma and the central nervous system.Cellular oncology (Dordrecht, Netherlands) · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Maren Nicole Stillger *Institute for Surgical Pathology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
Chia-Yi Chen *Institute for Surgical Pathology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
Zon Weng LaiInternal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA.
Mujia LiInstitute for Surgical Pathology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
Agnes SchäferDepartment of Neurosurgery, Philipps-University Marburg, Marburg, Germany.
Axel PagenstecherInstitute of Neuropathology, Philipps-University, Marburg, Germany.
Christopher NimskyDepartment of Neurosurgery, Philipps-University Marburg, Marburg, Germany.
Jörg Walter Bartsch *Department of Neurosurgery, Philipps-University Marburg, Marburg, Germany. jbartsch@med.uni-marburg.de.
Oliver Schilling *Institute for Surgical Pathology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
Philipps University of Marburg · DEUniversity of Freiburg · DEHeidelberg University · DEPfizer (United States) · US

Funding

by Rhön Klinikum AG FI_35_2016Deutsche Forschungsgemeinschaft 43198400 (SFB 1453 "NephGen")Deutsche Forschungsgemeinschaft 441891347 (SFB 1479 "OncoEscape")Federal Ministry of Education and Research (BMBF), ERANET PerMed Project "PerProGlio" 01KU1915Federal Ministry of Education and Research (BMBF), ERANET PerMed Project "PerProGlio" 01KU1915BGerman-Israeli Foundation for Scientific Research and Development grant no. 1444von-Behring-Röntgen Stiftung vBR 64-0018
6 · The paper itself

Abstract

backgroundGlioblastoma multiforme (GBM) is characterized by an unfavorable prognosis for patients affected. During standard-of-care chemotherapy using temozolomide (TMZ), tumors acquire resistance thereby causing tumor recurrence. Thus, deciphering essential molecular pathways causing TMZ resistance are of high therapeutic relevance.

methodsMass spectrometry based proteomics were used to study the GBM proteome. Immunohistochemistry staining of human GBM tissue for either calpain-1 or -2 was performed to locate expression of proteases. In vitro cell based assays were used to measure cell viability and survival of primary patient-derived GBM cells and established GBM cell lines after TMZ ± calpain inhibitor administration. shRNA expression knockdowns of either calpain-1 or calpain-2 were generated to study TMZ sensitivity of the specific subunits. The Comet assay and ɣH2AX signal measurements were performed in order to assess the DNA damage amount and recognition. Finally, quantitative real-time PCR of target proteins was applied to differentiate between transcriptional and post-translational regulation.

resultsCalcium-dependent calpain proteases, in particular calpain-2, are more abundant in glioblastoma compared to normal brain and increased in patient-matched initial and recurrent glioblastomas. On the cellular level, pharmacological calpain inhibition increased the sensitivities of primary glioblastoma cells towards TMZ. A genetic knockdown of calpain-2 in U251 cells led to increased caspase-3 cleavage and sensitivity to neocarzinostatin, which rapidly induces DNA strand breakage. We hypothesize that calpain-2 causes desensitization of tumor cells against TMZ by preventing strong DNA damage and subsequent apoptosis via post-translational TP53 inhibition. Indeed, proteomic comparison of U251 control vs. U251 calpain-2 knockdown cells highlights perturbed levels of numerous proteins involved in DNA damage response and downstream pathways affecting TP53 and NF-κB signaling. TP53 showed increased protein abundance, but no transcriptional regulation.

conclusionTMZ-induced cell death in the presence of calpain-2 expression appears to favor DNA repair and promote cell survival. We conclude from our experiments that calpain-2 expression represents a proteomic mode that is associated with higher resistance via "priming" GBM cells to TMZ chemotherapy. Thus, calpain-2 could serve as a prognostic factor for GBM outcome.

Indexed as

Calpain-1Calpain-2DNA damageGlioblastomaTemozolomide resistanceTP53U251N

Identifiers

PMID36932402
PMCPMC10022304
OpenAlexW4327811886

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read68
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.